Shares in stem cell penny stock Advanced Cell Technology, Inc. (OTCBB: ACTC.OB) dropped -1.12% on in its last trading session to close at $0.0880. ACTC’s total outstanding common stock is outrageous large at 2,029,049,544, almost all of which are floated in the OTC market, which the company has recently addressed in hopes of gaining the apporval of the penny stock’s shareholders in an ...
Advanced Cell Technology, Inc. (OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Aberdeen Royal Infirmary, the largest of the Grampian University Hospitals in Scotland, has been confirmed as a site for its Phase 1/2 human clinical trial for Stargardt’s Macular Dystrophy (SMD) using retinal ...
On Wednesday, January 25, 2012, Advanced Cell Technology, Inc. (OTCBB: ACTC) Chief Science Officer Robert Lanza filed SEC Form 4, as required for insider trading, indicating that he sold 7.7 million shares for $1.5 million, ending with 26.0 million shares after that sale.
http://www.sec.gov/Archives/edgar/data/1140098/000114420412003966/xslF345X03/v300304_4.xml
Advanced Cell Technology, Inc. (OTCBB: ACTC)
Advanced Cell Technology, Inc. is a biotechnology company. Millions of people globally depend on ACTC’s development of cellular therapies for the treatment of diseases and conditions. To bring patient-specific therapies from the laboratory to the patient, ACTC applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine.
